Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions
Priya Vart, Ricardo Correa-Rotter, Fan Fan Hou, Niels Jongs, Glenn M Chertow, Anna Maria Langkilde, John J V McMurray, Peter Rossing, C David Sjöström, Bergur V Stefansson, Robert D Toto, Walter Douthat, Elizabeth Escudero, Rey Isidto, Dinesh Khullar, Harpreet S Bajaj, David C Wheeler, Hiddo J L Heerspink, Priya Vart, Ricardo Correa-Rotter, Fan Fan Hou, Niels Jongs, Glenn M Chertow, Anna Maria Langkilde, John J V McMurray, Peter Rossing, C David Sjöström, Bergur V Stefansson, Robert D Toto, Walter Douthat, Elizabeth Escudero, Rey Isidto, Dinesh Khullar, Harpreet S Bajaj, David C Wheeler, Hiddo J L Heerspink
Abstract
Introduction: This study aimed to examine the efficacy and safety of dapagliflozin in the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial (NCT03036150) by geographic region.
Methods: Adults with chronic kidney disease (CKD) with or without type 2 diabetes, with estimated glomerular filtration rate (eGFR) 25 to 75 ml/min per 1.73 m2 and urinary albumin-to-creatinine ratio (UACR) 200 to 5000 mg/g were randomized to dapagliflozin (10 mg once daily) or placebo. The primary end point was a composite of a sustained decline in eGFR of ≥50%, end-stage kidney disease or death from kidney or cardiovascular causes. We categorized recruiting countries into 4 broad global regions: Asia, Europe, Latin America, and North America. Of 4304 randomized patients, 1346 (31.3%) were from Asia, 1233 (28.6%) from Europe, 912 (21.2%) from Latin America, and 813 (18.9%) from North America.
Results: The relative risk of the primary composite end point was lower in patients randomized to dapagliflozin (relative to placebo) in all regions, with hazard ratios (95% CI) of 0.70 (0.48-1.00), 0.60 (0.43-0.85), 0.61 (0.43-0.86), and 0.51 (0.34-0.76) among patients from Asia, Europe, Latin America, and North America, respectively. There was no effect modification by region (interaction P = 0.77). Occurrence of serious adverse events (SAEs) was lower among patients randomized to dapagliflozin versus placebo (21.9% vs. 26.8%, 34.1% vs. 38.6%, 29.8% vs. 31.5%, and 34.9% vs. 41.0% in Asia, Europe, Latin America, and North America, respectively).
Conclusion: Dapagliflozin reduced kidney and cardiovascular events and prolonged survival in patients with CKD, with and without type 2 diabetes, with no apparent effect modification by geographic region.
Keywords: SGLT-2 inhibitor; dapagliflozin; efficacy; regions; safety.
© 2022 International Society of Nephrology. Published by Elsevier Inc.
Figures
References
- Thiers F.A., Sinskey A.J., Berndt E.R. Trends in the globalization of clinical trials. Nat Rev Drug Discov. 2008;7:13–14.
- Vaduganathan M., Samman Tahhan A., Greene S.J., et al. Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years. Eur J Heart Fail. 2018;20:1068–1071. doi: 10.1002/ejhf.1130.
- Dewan P., Rorth R., Jhund P.S., et al. Income inequality and outcomes in heart failure: a global between-country analysis. JACC Heart Fail. 2019;7:336–346. doi: 10.1016/j.jchf.2018.11.005.
- Ferreira J.P., Rossignol P., Dewan P., et al. Income level and inequality as complement to geographical differences in cardiovascular trials. Am Heart J. 2019;218:66–74. doi: 10.1016/j.ahj.2019.08.019.
- Wanner C., Inzucchi S.E., Lachin J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334. doi: 10.1056/NEJMoa1515920.
- Neal B., Perkovic V., Mahaffey K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657. doi: 10.1056/NEJMoa1611925.
- Lam C.S.P., Ferreira J.P., Pfarr E., et al. Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J. 2021;42:4442–4451. doi: 10.1093/eurheartj/ehab360.
- Zannad F., Ferreira J.P., Pocock S.J., et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396:819–829. doi: 10.1016/S0140-6736(20)31824-9.
- Heerspink H.J.L., Stefánsson B.V., Correa-Rotter R., et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–1446. doi: 10.1056/NEJMoa2024816.
- Heerspink H.J.L., Stefansson B.V., Chertow G.M., et al. Rationale and protocol of the Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant. 2020;35:274–282. doi: 10.1093/ndt/gfz290.
- Wheeler D.C., Stefansson B.V., Batiushin M., et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant. 2020;35:1700–1711. doi: 10.1093/ndt/gfaa234.
- Wheeler D.C., Stefánsson B.V., Jongs N., et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9:22–31. doi: 10.1016/S2213-8587(20)30369-7.
- Perkovic V., Jardine M.J., Neal B., et al. Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–2306. doi: 10.1056/NEJMoa1811744.
- Wysham C.H., Bhattacharyya A., Tsoukas M., et al. Consistent outcomes with canagliflozin (CANA) in patients with Type 2 diabetes across geographic regions—results from the canagliflozin CardioVascular assessment study (CANVAS) program. Diabetes. 2018;67(suppl 1):1193.
- Cannon C.P., Pratley R., Dagogo-Jack S., et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425–1435. doi: 10.1056/NEJMoa2004967.
- Wiviott S.D., Raz I., Bonaca M.P., et al. Dapagliflozin and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2019;380:347–357. doi: 10.1056/NEJMoa1812389.
- Chan J.C., Malik V., Jia W., et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301:2129–2140. doi: 10.1001/jama.2009.726.
- Basu S., Yudkin J.S., Kehlenbrink S., et al. Estimation of global insulin use for type 2 diabetes, 2018–30: a microsimulation analysis [published correction appears in Lancet Diabetes Endocrinol. 2019;7:e1] Lancet Diabetes Endocrinol. 2019;7:25–33. doi: 10.1016/S2213-8587(18)30303-6.
- Kim Y.G., Hahn S., Oh T.J., et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56:696–708. doi: 10.1007/s00125-012-2827-3.
- Cai Y., Zeng T., Wen Z., Chen L. Ethnic differences in efficacy and safety of alogliptin: a systematic review and meta-analysis. Diabetes Ther. 2018;9:177–191. doi: 10.1007/s13300-017-0352-6.
Source: PubMed